Corcept Therapeutics Incorporated
CORT
Hisse Senetlerindeki Sıralama
#1818
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Hisse Fiyatı
$109.25
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$11.81B
Değişim (1 gün)
-3.64%
Değişim (1 yıl)
38.83%
Ülke
US
Ticaret Corcept Therapeutics Incorporated (CORT)
Kategori
Healthcare
Corcept Therapeutics Incorporated (CORT) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: 0.77%
Corcept Therapeutics Incorporated şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 0.77%'dir. 2023 yılı sonunda şirketin faaliyet marjı 22.24% idi.
Corcept Therapeutics Incorporated için 2001 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | 0.77% | -96.21% |
| 2024 | 20.29% | -8.77% |
| 2023 | 22.24% | -20.66% |
| 2022 | 28.03% | -17.58% |
| 2021 | 34.01% | -6.13% |
| 2020 | 36.23% | -0.49% |
| 2019 | 36.41% | 2.22% |
| 2018 | 35.62% | 7.29% |
| 2017 | 33.20% | 165.18% |
| 2016 | 12.52% | -282.77% |
| 2015 | -6.85% | -93.41% |
| 2014 | -104.02% | -74.04% |
| 2013 | -400.66% | -63.47% |
| 2012 | -1,096.82% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | -100.00% |
| 2009 | -69,827.59% | 641.22% |
| 2008 | -9,420.57% | 270.82% |
| 2007 | -2,540.46% | -70.80% |
| 2006 | -8,701.36% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 62.34% | -19.04% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 29.76% | -61.35% |
HK
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.